Moderna's Cancer Vaccine Shows Promising Phase 3 Results
Moderna (NASDAQ: MRNA) has achieved significant progress with its investigational personalized cancer vaccine, intismeran autogene. The phase 3 clinical trial results showed meaningful improvements in recurrence-free survival for melanoma patients, marking a major milestone beyond the company's successful Spikevax COVID-19 vaccine. This development addresses concerns about Moderna’s ability to expand into oncology and validate its mRNA technology outside of infectious diseases. While demand for coronavirus vaccines has declined, intismeran autogene could become a long-term revenue driver with potential applications in lung, bladder, and kidney cancers. Analysts estimate it may generate up to $16.8 billion by 2035, despite slower growth compared to Spikevax's pandemic-driven peak sales of nearly $18.4 billion. Moderna is collaborating with Merck (NYSE: MRK) on the cancer vaccine and remains unprofitable but has a strong pipeline across infectious diseases and oncology.
Topics: cancer vaccine clinical trials Moderna mRNA technology